GC Biopharma Corp. (KRX:006280)
South Korea · Delayed Price · Currency is KRW 142,300
+3,900 (2.82%)
Last updated: Apr 8, 2026, 2:06 PM KST
GC Biopharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,991,279 | 1,679,892 | 1,626,644 | 1,711,313 | 1,537,826 |
Other Revenue | -0 | - | -0 | -0 | -0 |
| 1,991,279 | 1,679,892 | 1,626,644 | 1,711,313 | 1,537,826 | |
Revenue Growth (YoY) | 18.54% | 3.27% | -4.95% | 11.28% | 2.24% |
Cost of Revenue | 1,438,637 | 1,199,348 | 1,143,313 | 1,131,350 | 1,018,585 |
Gross Profit | 552,642 | 480,544 | 483,331 | 579,962 | 519,240 |
Selling, General & Admin | 306,689 | 265,470 | 258,898 | 292,484 | 282,771 |
Research & Development | 152,945 | 166,198 | 173,487 | 191,347 | 146,030 |
Amortization of Goodwill & Intangibles | 10,657 | 6,695 | 4,985 | 3,856 | 2,087 |
Other Operating Expenses | 1,387 | 1,277 | 1,624 | 2,165 | 1,594 |
Operating Expenses | 484,833 | 448,505 | 449,420 | 499,253 | 445,515 |
Operating Income | 67,809 | 32,039 | 33,911 | 80,710 | 73,726 |
Interest Expense | -50,297 | -40,439 | -28,483 | -18,393 | -12,501 |
Interest & Investment Income | 3,121 | 3,621 | 3,421 | 3,785 | 1,665 |
Earnings From Equity Investments | 42,030 | 1,250 | - | 40,467 | - |
Currency Exchange Gain (Loss) | -1,847 | 7,245 | 1,010 | 2,570 | 13,477 |
Other Non Operating Income (Expenses) | -5,268 | -1,440 | 3,147 | -4,842 | 8,002 |
EBT Excluding Unusual Items | 55,548 | 2,276 | 13,006 | 104,296 | 84,368 |
Gain (Loss) on Sale of Investments | 5,202 | -20,799 | -37,222 | -18,759 | 81,200 |
Gain (Loss) on Sale of Assets | -1,163 | -3,761 | -2,919 | 190 | 6,991 |
Asset Writedown | -94,770 | -18,088 | - | - | - |
Other Unusual Items | -148 | -738 | - | - | - |
Pretax Income | -35,331 | -41,110 | -27,135 | 85,728 | 172,559 |
Income Tax Expense | -5,646 | 1,527 | -7,326 | 16,313 | 35,609 |
Earnings From Continuing Operations | -29,685 | -42,637 | -19,809 | 69,415 | 136,950 |
Net Income to Company | -29,685 | -42,637 | -19,809 | 69,415 | 136,950 |
Minority Interest in Earnings | 25,011 | 16,357 | -6,823 | -3,962 | -13,738 |
Net Income | -4,674 | -26,280 | -26,632 | 65,453 | 123,212 |
Net Income to Common | -4,674 | -26,280 | -26,632 | 65,453 | 123,212 |
Net Income Growth | - | - | - | -46.88% | 52.02% |
Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 |
EPS (Basic) | -409.51 | -2302.63 | -2333.42 | 5734.87 | 10795.57 |
EPS (Diluted) | -410.00 | -2303.00 | -2333.42 | 5734.87 | 10795.57 |
EPS Growth | - | - | - | -46.88% | 52.02% |
Free Cash Flow | 27,101 | -85,452 | -84,560 | 61,158 | 23,658 |
Free Cash Flow Per Share | 2374.52 | -7487.16 | -7408.97 | 5358.56 | 2072.84 |
Gross Margin | 27.75% | 28.61% | 29.71% | 33.89% | 33.77% |
Operating Margin | 3.40% | 1.91% | 2.08% | 4.72% | 4.79% |
Profit Margin | -0.24% | -1.56% | -1.64% | 3.82% | 8.01% |
Free Cash Flow Margin | 1.36% | -5.09% | -5.20% | 3.57% | 1.54% |
EBITDA | 155,464 | 113,074 | 109,810 | 145,806 | 129,630 |
EBITDA Margin | 7.81% | 6.73% | 6.75% | 8.52% | 8.43% |
D&A For EBITDA | 87,655 | 81,034 | 75,899 | 65,096 | 55,904 |
EBIT | 67,809 | 32,039 | 33,911 | 80,710 | 73,726 |
EBIT Margin | 3.40% | 1.91% | 2.08% | 4.72% | 4.79% |
Effective Tax Rate | - | - | - | 19.03% | 20.64% |
Advertising Expenses | 43,859 | 35,238 | 40,739 | 50,726 | 49,015 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.